anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The pharmacokinetics of XELODA and its metabolites have been evaluated in about 200 cancer patients over a dosage range of 500 to 3500 mg/m2/day. Over this range, the pharmacokinetics of XELODA and its metabolite, 5'-DFCR were dose proportional and did not change over time. The increases in the AUCs of 5'-DFUR and 5-FU, however, were greater than proportional to the increase in dose and the AUC of 5-FU was 34% higher on day 14 than on day 1. The elimination half-life of both parent capecitabine and 5-FU was about ¾ of an hour. The inter-patient variability in the Cmax and AUC of 5-FU was greater than 85%.

Following oral administration of 825 mg/m2 capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for capecitabine than the Caucasian patients (n=22). Japanese patients had also about 25% lower Cmax and 34% lower AUC for FBAL than the Caucasian patients. The clinical significance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5'-DFCR, 5'-DFUR, and 5-FU).
Systems and methods can support presenting patient alarms to clinical care users. An alarm management system can maintain a mapping of patients to users as well as user context information. The alarm management system can receive alarm indications from medical devices associated with the patients along with alarm context information associated with the alarm indication. The alarm management system can determine a target user among the users according to evaluating the mapping of patients to users, the user context information, and the alarm context information. The alarm management system can determine a notification modality according to evaluating the alarm indication, the target user, a portion of the user context information associated with the target user, and the alarm context information. The alarm management system can transmit the alarm indication, the alarm context information, and the notification modality to a mobile device for presentation to the target user.
The invention belongs to the fields of chemistry and pharmacy and in particular relates to 9-O-glucoside-berberine salt. The 9-O-glucoside-berberine salt has a general formula shown as specifications, wherein R is a monosaccharide group or a disaccharide group; and X- is halideion. The invention also relates to a preparation method of the 9-O-glucoside-berberine salt. The preparation method comprises the following steps of: converting berberine into berberrubine; reacting the berberrubine with acetylated halogeno sugar to prepare 9-O-acetylated glucoside-berberine; and performing a reaction under an alkaline condition to remove acetyl to prepare the 9-O-glucoside-berberine salt. Compared with berberine salt, the 9-O-glucoside-berberine salt has higher antibacterial, blood fat-reducing and blood sugar-reducing activities. The preparation method is simple, convenient and practicable, high in yield and low in cost. The 9-O-glucoside-berberine salt can serve as an active ingredient for preparing high-efficiency, safe and novel antibacterial, blood fat-reducing and blood sugar-reducing medicaments and has a good application prospect.
PROBLEM TO BE SOLVED: To obtain a cosmetic sunscreen composition that contains a sunscreen agent treated with improved thickener and stabilizer, thus has sufficiently thickened viscosity giving aesthetically pleasant feeling. SOLUTION: This cosmetic emulsion composition includes 1-99 wt.% of water, 0.1-30 wt.% of an emollient oil, 0.1-30 wt.% of a sunscreen agent that is active in the ultraviolet range of from 290 to 400 nm and 0.1-5 wt.% of an aluminum salt of a 1-8C carboxylic acid. The sun screening agent is preferably zinc oxide, titanium oxide and their mixture. Particularly octylmethoxy cinnamate, benzophenone-3 are preferred as a sun screening agent. The emollient oil is preferably cyclomethicone, dimethicone copolyol and their mixture. As the aluminum salt, is preferred aluminum citrate. This cosmetic composition is preferably a water-in-oil type emulsion.
A previous study found a variety of unusual sexual interests to cluster in a five-factor structure, namely submission/masochism, forbidden sexual activities, dominance/sadism, mysophilia, and fetishism (Schippers et al., 2021). The current study was an empirical replication to examine whether these findings generalized to a representative population sample. An online, anonymous sample (N = 256) representative of the Dutch adult male population rated 32 unusual sexual interests on a scale from 1 (very unappealing) to 7 (very appealing). An exploratory factor analysis assessed whether similar factors would emerge as in the original study. A subsequent confirmatory factor analysis served to confirm the factor structure. Four slightly different factors of sexual interest were found: extreme, illegal and mysophilic sexual activities; light BDSM without real pain or suffering; heavy BDSM that may include pain or suffering; and illegal but lower-sentenced and fetishistic sexual activities. The model fit was acceptable. The representative replication sample was more sexually conservative and showed less sexual engagement than the original convenience sample. On a fundamental level, sexual interest in light BDSM activities and extreme, forbidden, and mysophilic activities seem to be relatively separate constructs.
A multi-functional computer-assisted gastroscopy system employing an optimized integrated AI solution is disclosed. The system utilizes multiple deep-learning neural models to achieve low latency and high performance requirements for multiple tasks. Optimization is performed at three levels: an architecture level, a modular level, and a functional level. At the architecture level, the model is designed in a way that the HP infection classification and some lesions can be simultaneously completed by carrying out reasoning once, so that the calculation cost can be reduced. On the modularization level, as a sub model of HP infection classification, the partial recognition model is optimized by utilizing time information. It not only improves the performance of HP infection classification, but also has important function for detecting pathological changes and determining program status. At the functional level, reasoning delay is reduced to the minimum through configuration and resource perception optimization. Also at the functional level, the pre-processing is accelerated by image resizing parallelization and unified pre-processing.
The invention discloses medical depilatory cream and a preparation method thereof, and relates to the technical field of depilatory cream. The medical depilatory cream is prepared from the following materials in parts by weight: 6-8 parts of calcium thioglycolate trihydrate, 2-4 parts of stearyl alcohol, 2-4 parts of cetanol, 12-16 parts of vaseline, 8-10 parts of liquid paraffin, 4-8 parts of glycerol, 4-8 parts of hydroxyethyl stearate, 4-8 parts of polyoxyethylene aliphatic alcohol ether, 0.5-1.5 parts of poloxamer, 0.001-0.1 part of a synthetic antiseptic antibacterial agent, and 50-60 parts of deionized water. The invention also discloses a preparation method of the medical depilatory cream. An external antiseptic antibacterial agent is added to common depilatory, so that the medical depilatory cream has the function of killing the bacteria at the skin surface when unhairing, and restrains growth of the bacteria within a certain period of time. The medical depilatory cream is small in thrill of used auxiliary material; and hair follicles can be effectively protected. Therefore, the medical depilatory cream is simple to prepare, convenient to use, and dedicated to skin preparation before an operation, and has antiseptic and antibacterial effects.
BACKGROUND AND OBJECTIVES: Nosocomial infections are the most common complication among critically ill patients and contribute to poor long-term outcomes. Patients with aneurysmal subarachnoid hemorrhage (aSAH) are highly susceptible to perioperative infections, yet it is unclear what factors influence infection onset and functional recovery. The objective was to investigate risk factors for perioperative infections after aSAH and relate causative pathogens to patient outcomes.
METHODS: Clinical records were obtained for 194 adult patients with aSAH treated at our institution from 2016 to 2020. Demographics, clinical course, complications, microbiological reports, and outcomes were collected. χ 2 , univariate, and multivariate logistic regression analyses were used to analyze risk factors.
RESULTS: Nearly half of the patients developed nosocomial infections, most frequently pneumonia and urinary tract infection. Patients with infections had longer hospital stays, higher rates of delayed cerebral ischemia, and worse functional recovery up to 6 months after initial hemorrhage. Independent risk factors for pneumonia included male sex, comatose status at admission, mechanical ventilatory use, and longer admission, while those for urinary tract infection included older age and longer admission. Staphylococcus , Klebsiella , and Enterococcus spp. were associated with poor long-term outcome. Certain pathogenic organisms were associated with delayed cerebral ischemia.
CONCLUSION: Perioperative infections are highly prevalent among patients with aSAH and are related to adverse outcomes. The risk profiles for nosocomial infections are distinct to each infection type and causative organism. Although strong infection control measures should be universally applied, patient management must be individualized in the context of specific infections.
Type 2 diabetes (T2D) increases fracture incidence and fracture-related mortality rates (KK.Cg-Ay/J. The Jackson Laboratory; Available from: https://www.jax.org/strain/002468 ). While numerous mouse models for T2D exist, few effectively stimulate persistent hyperglycemia in both sexes, and even fewer are suitable for bone studies. Commonly used models like db/db and ob/ob have altered leptin pathways, confounding bone-related findings since leptin regulates bone properties (Fajardo et al. in Journal of Bone and Mineral Research 29(5): 1025-1040, 2014). The Yellow Kuo Kondo (KK/Ay) mouse, a polygenic mutation model of T2D, is able to produce a consistent diabetic state in both sexes and addresses the lack of a suitable model of T2D for bone studies. The diabetic state of KK/Ay stems from a mutation in the agouti gene, responsible for coat color in mice. This mutation induces ectopic gene expression across various tissue types, resulting in diabetic mice with yellow fur coats (Moussa and Claycombe in Obesity Research 7(5): 506-514, 1999). Male and female KK/Ay mice exhibited persistent hyperglycemia, defining them as diabetic with blood glucose (BG) levels consistently exceeding 300 mg/dL. Notably, male control mice in this study were also diabetic, presenting a significant limitation. Nevertheless, male and female KK/Ay mice showed significantly elevated BG levels, HbA1c, and serum insulin concentration when compared to the non-diabetic female control mice. Early stages of T2D are characterized by hyperglycemia and hyperinsulinemia resulting from cellular insulin resistance, whereas later stages may feature hypoinsulinemia due to β-cell apoptosis (Banday et al. Avicenna Journal of Medicine 10(04): 174-188, 2020 and Klein et al. Cell Metabolism 34(1): 11-20, 2022). The observed hyperglycemia, hyperinsulinemia, and the absence of differences in β-cell mass suggest that KK/Ay mice in this study are modeling the earlier stages of T2D. While compromised bone microarchitecture was observed in this study, older KK/Ay mice, representing more advanced stages of T2D, might exhibit more pronounced skeletal manifestations. Compared to the control group, the femora of KK/Ay mice had higher cortical area and cortical thickness, and improved trabecular properties which would typically be indicative of greater bone strength. However, KK/Ay mice displayed lower cortical tissue mineral density in both sexes and increased cortical porosity in females. Fracture instability toughness of the femora was lower in KK/Ay mice overall compared to controls. These findings indicate that decreased mechanical integrity noted in the femora of KK/Ay mice was likely due to overall bone quality being compromised.
Background: Laparoscopic totally extraperitoneal (TEP) inguinal hernia repair (IHR) reduces risk of injury to intraperitoneal structures. Balloon dissection is more costly and has theoretical risk of injury to the surrounding structures compared with telescopic dissection (TD). This study aims to evaluate the learning curve (LC) for TEP IHR with TD of a single surgeon. Methods: This is a 3-year retrospective cohort study from January 2020 to December 2022 on patients who underwent elective laparoscopic TEP unilateral IHR with TD. Exclusion criteria were recurrent inguinal hernia. Cumulative sum (CUSUM) analysis was performed to evaluate the number of cases required to surmount the LC, that is, NLC for operating time (OT) and open conversion. One way analysis of variance was used to perform groupwise comparison. Results: There were 69 patients who underwent laparoscopic TEP unilateral IHR with TD. The median age was 58.0 years (range 24.0-80.0) and body mass index was 23.0 (range 18.6-30.0). Majority of the hernia was indirect (n = 48, 69.6%). The median OT was 70 minutes (range 35-210). Three cases (4.3%) had open conversion. One-year recurrence was 4.2% (n = 1/24). CUSUM analysis showed improvement in OT after the eighth case. However, this was followed by multiple inflection points with no apparent stabilization in OT. Pairwise comparison showed a decrease in OT between cases 18-36 and cases 37-54. There was no incidence of open conversion until the 56th case. Conclusion: Laparoscopic TEP IHR using TD is safe in the absence of a practor. A minimum of 36 cases is required to surmount the initial LC.
With the clinical application of three-dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT), radiotherapy (RT) has shown important role in the treatment of hepatocellular carcinoma (HCC). Meta-analysis has demonstrated that transcatheter arterial chemoembolization (TACE) combined RT was more therapeutically beneficial than TACE alone. Especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis, or lymph node involved, RT was more effective than other treatment methods. Previous studies had showed that RT could receive response rate of 50% to 60% for HCC with PVTT. But for those patients, high accidence of out RT field failure of liver and distance metastasis was found. Effective systemic therapy was necessary to advanced HCC. Based on two phase III trials, sorafenib was recommended as systemic therapy to advanced HCC. But tumor response rate of sorafenib alone was only 2.3-3% by RICIST criteria. More than half of patients was received survival benefit by maintaining in stable disease. It is feasible to improve survival by combining IMRT and sorafenib for advanced HCC with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis, or lymph node involved. In addition, it was demonstrated that sorafenib could potentiate irradiation in HCC cell lines through inhibiting radiation-induced proliferation and DNA repair and promoting radiation-induced apoptosis.
A solution for peritoneal dialysis or infusion comprises two separate solutions in a double-chambered pouch, one of which (containing calcium ions and glucose) is acidified to a pH of less than 3.2, while the other contains bicarbonate.  A solution for peritoneal dialysis or infusion comprises two separate solutions, which are mixed together after heat sterilization.  One solution contains calcium ions, other electrolyte salts and glucose in an osmotically active concentration, while the other solution contains bicarbonate and the salt of a weak acid with a pKa of less than 5.  The first solution is acidified with a physiologically acceptable acid to give a pH of less than 3.2, and the bicarbonate content of the second solution is fixed so that the concentration of bicarbonate does not exceed 10 mmol/l.   An Independent claim is also included for a double-chambered pouch for the two solutions, which is made of plastic.  The wall separating the two solutions may be broken by applying pressure to either of the chambers.
Both pain and mental health conditions are common among young people. They often co-occur, but we wanted to investigate further whether it is pain (abdominal pain, headache, musculoskeletal pain, menstrual pain) that precedes mental health conditions (depression, anxiety, stress, phobia) or whether it is the other way around, mental health conditions that precede pain. Using electronic health records-the Skåne Healthcare Register-we identified and followed young people aged 7 to 18 over a 13-year period and tracked all their registered diagnoses. Using Poisson regression, we analyzed the incidence rate ratio (IRR) of being diagnosed with mental health conditions after an initial diagnosis of pain and vice versa the IRR of being diagnosed with pain after an initial diagnosis of a mental health condition. Among individuals with pain, 12,054 (23%) later received a diagnosis of a mental health condition. The IRR for a mental health condition after pain was 2.86 (95% (confidence interval) CI = 2.78-2.94) compared to not having pain, adjusted for age, sex, and prior health care consultations. Among individuals with mental health conditions, 3,688 (17%) later received a diagnosis of pain. The adjusted IRR was 1.57 (95% CI = 1.52-1.63). Compared to boys, girls had consistently higher estimates, and the same was found for the younger individuals compared to the older ones. Individuals with pain have a 3-fold increased risk of developing mental health conditions, while the risk of developing pain after mental health conditions was lower although still elevated compared to young people seeking care regardless of cause. PERSPECTIVE: Young people with pain have a 3-fold increased risk of developing mental health conditions, while the reverse risk is lower but still elevated compared to young people without these conditions. Health care professionals must recognize the interplay between pain and mental health in young patients when diagnosing and planning treatment.
This is an open-label, prospective, multi-center single-arm phase II trial. Patients with oligometastatic extensive stage SCLC will be enrolled in the trial. In this trial oligometastatic disease is defined as up to five tumor lesions, whereas the primary tumor including mediastinal lymph node metastases counts as one tumor lesion. The primary tumor including lymph node metastases must be suitable for radiochemotherapy and all distant metastases for stereotactic radiotherapy. Patients must have completed systemic therapy with two cycles of platinum/etoposide/durvalumab and have stable disease or partial response according to RECIST 1.1 criteria. After study inclusion, patients receive radiochemotherapy with concomitant durvalumab (MEDI4736). Concomitant chemotherapy consists of further two cycles platinum/etoposide q3w (summarized cycle 3-4). Dosing of chemotherapy is etoposide 90mg/m² body surface area (BSA) day 1-3 in combination with cisplatin 75mg/m² BSA on day 1 or carboplatin area under the curve (AUC) 5 mg/ml per minute on day 1. Split dose of platinum chemotherapy to 2-3 days is an allowed treatment option. Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment. Radiotherapy to the primary tumor including mediastinal lymph node metastases is delivered in single fractions of 1.8Gy once daily up to a cumulative dose of 63.0Gy by intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT). In the following, stereotactic radiotherapy is delivered to the up to four further tumor locations during durvalumab maintenance therapy. Sequencing of radiotherapy of the primary tumor and metastases may be changed if radiotherapy of brain, vertebral or other symptomatic metastases is urgently necessary. Stereotactic radiotherapy will be performed according to local standards with established dose and fractionation schemes in ablative doses depending on the affected organ system.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to novel derivatives of carbamic acid of the general formula (I)   where R 1  and R 2  mean independently each of other alkyl, aryl, aralkyl, heteroaryl, cycloalkyl or heterocyclyl; R 3  and R 4  means independently each of other hydrogen atom, alkyl, halogen atom, hydroxyl or aryl; R 5  means -CCO-R 6  where R 6  means hydrogen atom or alkyl; A means alkylene or alkenylene; B means -O(CH 2 ) m - or -(CH 2 ) n -; m means the whole number from 1 to 8; n means the whole number from 0 to 8, or to their racemates or individual isomers or to their novel pharmaceutically acceptable salts or solvates. Invention can be used as therapeutic medicinal agents. Invention relates to also method of synthesis of these compounds, pharmaceutical composition based on the novel derivatives of carbamic acid and method of treatment of patients with morbid state associated with intermittent lameness. EFFECT: new compounds indicated above, improved method of synthesis, valuable medicinal properties. 20 cl, 2 tbl, 25 ex _
The recommended starting dose of AXIRON (testosterone) topical solution is 60 mg of testosterone (2 pump actuations) applied once daily. 

To ensure proper dosing, serum testosterone concentrations should be measured after initiation of therapy to ensure that the desired concentrations (300 ng/dL-1050 ng/dL) are achieved. The AXIRON dose can be adjusted based on the serum testosterone concentration from a single blood draw 2 – 8 hours after applying AXIRON and at least 14 days after starting treatment or following dose adjustment. 

If the measured serum testosterone concentration is below 300 ng/dL, the daily testosterone dose may be increased from 60 mg (2 pump actuations) to 90 mg (3 pump actuations) or from 90 mg to 120 mg (4 pump actuations). If the serum testosterone concentration exceeds 1050 ng/dL, the daily testosterone dose should be decreased from 60 mg (2 pump actuations) to 30 mg (1 pump actuation) as instructed by a physician. If the serum testosterone concentration consistently exceeds 1050 ng/dL at the lowest daily dose of 30 mg (1 pump actuation), AXIRON therapy should be discontinued. 

The application site and dose of AXIRON are not interchangeable with other topical testosterone products.